JP7614842B2 - 抗原性エプスタインバーウイルスポリペプチド - Google Patents

抗原性エプスタインバーウイルスポリペプチド Download PDF

Info

Publication number
JP7614842B2
JP7614842B2 JP2020554517A JP2020554517A JP7614842B2 JP 7614842 B2 JP7614842 B2 JP 7614842B2 JP 2020554517 A JP2020554517 A JP 2020554517A JP 2020554517 A JP2020554517 A JP 2020554517A JP 7614842 B2 JP7614842 B2 JP 7614842B2
Authority
JP
Japan
Prior art keywords
ferritin
polypeptide
seq
amino acid
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519598A (ja
JPWO2019195314A5 (https=
JP2021519598A5 (https=
Inventor
ゲイリー・ジェイ・ナーベル
チィ－ジェン・ウェイ
ローラ・ニュエン
カート・スワンソン
テ－フイ・チョウ
ステファン・コースター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2021519598A publication Critical patent/JP2021519598A/ja
Publication of JPWO2019195314A5 publication Critical patent/JPWO2019195314A5/ja
Publication of JP2021519598A5 publication Critical patent/JP2021519598A5/ja
Priority to JP2023145164A priority Critical patent/JP7719134B2/ja
Application granted granted Critical
Publication of JP7614842B2 publication Critical patent/JP7614842B2/ja
Priority to JP2025123756A priority patent/JP2025166834A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020554517A 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド Active JP7614842B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023145164A JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド
JP2025123756A JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652201P 2018-04-03 2018-04-03
US62/652,201 2018-04-03
PCT/US2019/025419 WO2019195314A2 (en) 2018-04-03 2019-04-02 Antigenic epstein barr virus polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145164A Division JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド

Publications (4)

Publication Number Publication Date
JP2021519598A JP2021519598A (ja) 2021-08-12
JPWO2019195314A5 JPWO2019195314A5 (https=) 2022-04-07
JP2021519598A5 JP2021519598A5 (https=) 2022-04-07
JP7614842B2 true JP7614842B2 (ja) 2025-01-16

Family

ID=66821298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554517A Active JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
JP2023145164A Active JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド
JP2025123756A Pending JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023145164A Active JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド
JP2025123756A Pending JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Country Status (5)

Country Link
US (4) US11617780B2 (https=)
EP (1) EP3773708A2 (https=)
JP (3) JP7614842B2 (https=)
CN (1) CN112512566A (https=)
WO (1) WO2019195314A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
US12276665B2 (en) * 2018-07-20 2025-04-15 Aicuris Anti-Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CN111154803B (zh) * 2020-01-10 2022-07-22 新乡医学院 一种重组EBV gHgL免疫原的制备方法及其应用
US20230145420A1 (en) * 2020-04-10 2023-05-11 Vanderbilt University Recombinant vaccines and methods of use thereof
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
CN113144187B (zh) * 2021-01-28 2024-03-22 安徽智飞龙科马生物制药有限公司 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用
US20240207392A1 (en) * 2021-04-13 2024-06-27 Modernatx, Inc. Epstein-barr virus mrna vaccines
US20250281605A1 (en) * 2024-03-08 2025-09-11 Sanofi Antigenic Epstein Barr Virus Polypeptides
WO2025215618A1 (en) * 2024-04-12 2025-10-16 Seqirus Inc. Methods and reagents for treating or preventing ebv
CN120365380A (zh) * 2025-04-21 2025-07-25 易康生物(苏州)有限公司 一种嵌合设计的eb病毒抗原及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506565A (ja) 2007-12-21 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012225885A (ja) 2011-04-22 2012-11-15 Nara Institute Of Science & Technology 被検物質の電気化学的検出方法
JP2014513678A (ja) 2011-04-07 2014-06-05 ネオトープ バイオサイエンシーズ リミテッド Ｉｃ３ｂ沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
JP2015530369A (ja) 2012-07-26 2015-10-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
JP2020520674A (ja) 2017-04-19 2020-07-16 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ ワクチン及び標的としてのプラスモジウムスポロゾイトｎｐｄｐペプチド、新規マラリアワクチン、及びそれに結合する抗体
JP2021504445A (ja) 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP1504037B1 (en) 2002-05-10 2009-12-30 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
JP5492418B2 (ja) 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7951770B2 (en) 2007-06-13 2011-05-31 Northwestern University Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process
WO2009126816A1 (en) 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
EP3705133B1 (en) 2010-05-14 2024-06-26 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
JP2013541507A (ja) 2010-08-25 2013-11-14 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） エプスタイン・バール・ウイルスワクチン
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
AU2014362234B2 (en) 2013-12-11 2019-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA2950085A1 (en) 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
KR20180088458A (ko) 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
EP3463444B1 (en) 2016-06-07 2024-10-16 Deutsches Krebsforschungszentrum Improvement of hpv l2 peptide immunogenicity
FI3471760T3 (fi) 2016-06-17 2025-01-27 Boehringer Ingelheim Vetmedica Gmbh Lineaarisia tai haaroittuneita polyakryylihappopolymeeriadjuvantteja käsittäviä uusia immunogeenisiä formulaatioita
US11572389B2 (en) 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US11389529B2 (en) 2017-07-13 2022-07-19 City Of Hope Expression system for expressing herpesvirus glycoprotein complexes
US11964006B2 (en) 2017-09-16 2024-04-23 City Of Hope Multivalent Epstein-Barr virus-like particles and uses thereof
WO2019161163A1 (en) 2018-02-16 2019-08-22 The Wistar Institute Of Anatomy And Biology Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512565A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性流感-铁蛋白多肽
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
US20230016245A1 (en) 2021-07-16 2023-01-19 California Institute Of Technology Stoichiometric expression of messenger polycistrons

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506565A (ja) 2007-12-21 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2014513678A (ja) 2011-04-07 2014-06-05 ネオトープ バイオサイエンシーズ リミテッド Ｉｃ３ｂ沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法
JP2012225885A (ja) 2011-04-22 2012-11-15 Nara Institute Of Science & Technology 被検物質の電気化学的検出方法
JP2015530369A (ja) 2012-07-26 2015-10-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
JP2020520674A (ja) 2017-04-19 2020-07-16 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ ワクチン及び標的としてのプラスモジウムスポロゾイトｎｐｄｐペプチド、新規マラリアワクチン、及びそれに結合する抗体
JP2021504445A (ja) 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン

Also Published As

Publication number Publication date
JP2021519598A (ja) 2021-08-12
WO2019195314A3 (en) 2019-11-07
JP7719134B2 (ja) 2025-08-05
WO2019195314A2 (en) 2019-10-10
EP3773708A2 (en) 2021-02-17
US20250127847A1 (en) 2025-04-24
US20210015896A1 (en) 2021-01-21
US20240050518A1 (en) 2024-02-15
US12053503B2 (en) 2024-08-06
JP2023179457A (ja) 2023-12-19
US20230277619A1 (en) 2023-09-07
US11617780B2 (en) 2023-04-04
US12121562B2 (en) 2024-10-22
JP2025166834A (ja) 2025-11-06
CN112512566A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
JP7719134B2 (ja) 抗原性エプスタインバーウイルスポリペプチド
US11993636B2 (en) Antigenic OspA polypeptides
JP7614841B2 (ja) 抗原性呼吸器合胞体ウイルスポリペプチド
US11904009B2 (en) Ferritin proteins
JP2024041980A (ja) 抗原性インフルエンザ－フェリチンポリペプチド
JP7505788B2 (ja) Ｃ９ｏｒｆ７２に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト
RU2807992C2 (ru) Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса
RU2816208C2 (ru) АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241227

R150 Certificate of patent or registration of utility model

Ref document number: 7614842

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150